Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115277) titled 'Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
Primary Sponsor: Sinotau Pharmaceutical Group
Condition:
Prostate Cancer
Intervention:
Drug: Flotufolastat F-18 Injection
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: March 14, 2025
Target Sample Size: 121
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/sh...